Former FDA Medical Policy Head Joins Greenleaf, Will Highlight FDA As “Resource”
Rachel Sherman to expand drug capacity at FDA-centered consultancy, following 25 years at agency.
You may also be interested in...
Rachel Sherman takes over a position that has not been filled permanently since Josh Sharfstein left in 2011.
After months of speculation, FDA veteran Rachel Sherman becomes deputy commissioner for medical products and tobacco.
Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.